PA3670 / Palo Alto Pharma - LARVOL DELTA

Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: Zhejiang Palo Alto Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial primary completion date: Jun 2023 ➔ Oct 2023

Trial completion • Trial primary completion date • Hepatitis B • Infectious Disease

Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Zhejiang Palo Alto Pharmaceuticals, Inc.

New P1 trial • Hepatitis B • Infectious Disease